1. Home
  2. QLGN vs CRKN Comparison

QLGN vs CRKN Comparison

Compare QLGN & CRKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • CRKN
  • Stock Information
  • Founded
  • QLGN 1996
  • CRKN 2015
  • Country
  • QLGN United States
  • CRKN United States
  • Employees
  • QLGN N/A
  • CRKN N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • CRKN Industrial Machinery/Components
  • Sector
  • QLGN Health Care
  • CRKN Technology
  • Exchange
  • QLGN Nasdaq
  • CRKN Nasdaq
  • Market Cap
  • QLGN 2.4M
  • CRKN 2.6M
  • IPO Year
  • QLGN N/A
  • CRKN N/A
  • Fundamental
  • Price
  • QLGN $3.55
  • CRKN $4.55
  • Analyst Decision
  • QLGN
  • CRKN
  • Analyst Count
  • QLGN 0
  • CRKN 0
  • Target Price
  • QLGN N/A
  • CRKN N/A
  • AVG Volume (30 Days)
  • QLGN 110.9K
  • CRKN 319.8K
  • Earning Date
  • QLGN 04-07-2025
  • CRKN 03-31-2025
  • Dividend Yield
  • QLGN N/A
  • CRKN N/A
  • EPS Growth
  • QLGN N/A
  • CRKN N/A
  • EPS
  • QLGN N/A
  • CRKN N/A
  • Revenue
  • QLGN N/A
  • CRKN $13,461,000.00
  • Revenue This Year
  • QLGN N/A
  • CRKN N/A
  • Revenue Next Year
  • QLGN N/A
  • CRKN N/A
  • P/E Ratio
  • QLGN N/A
  • CRKN N/A
  • Revenue Growth
  • QLGN N/A
  • CRKN 22715.25
  • 52 Week Low
  • QLGN $2.96
  • CRKN $4.26
  • 52 Week High
  • QLGN $29.45
  • CRKN $13,500.00
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 47.06
  • CRKN 22.44
  • Support Level
  • QLGN $3.16
  • CRKN $6.01
  • Resistance Level
  • QLGN $3.75
  • CRKN $7.34
  • Average True Range (ATR)
  • QLGN 0.21
  • CRKN 0.68
  • MACD
  • QLGN 0.06
  • CRKN 0.97
  • Stochastic Oscillator
  • QLGN 67.25
  • CRKN 8.95

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

About CRKN Crown Electrokinetics Corp.

Crown ElectroKinetics Corp is a provider of DynamicTint. The company's technology allows any glass surface to transition between clear and dark in seconds. DynamicTint allows windows to transition from transparent to black. With applications to a wide array of windows, including commercial buildings, automotive sunroofs, and residential skylights, Crown partners with glass and film manufacturers for mass production and distribution. Its technology is a thin film that is powered by an electrically-charged pigment which not only replaces common window tints but is also a more sustainable alternative to traditional window treatments. It is supported by a robust patent portfolio.

Share on Social Networks: